LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

LLY

1,085.2

+0.72%↑

JNJ

232.02

+0.81%↑

ABBV

214.96

+0.42%↑

UNH

382.27

+0.74%↑

AZN

188.04

+0.25%↑

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

11.16 -5.74

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.29

Massimo

11.82

Metriche Chiave
By Trading Economics
Entrata	227M
Vendite	139M
P/E Media del settore	4.522 50.102
Margine di Profitto	163.843
Dipendenti	1,796
EBITDA	1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+66.81% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.1B
Apertura precedente	16.9
Chiusura precedente	11.16

Notizie sul Sentiment di mercato

By Acuity

10%

90%

7 / 344 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 mag 2026, 16:52 UTC

Principali Notizie su Eventi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q EPS $11.61 >WEBC

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q Sales $179.6M >WEBC

26 mag 2026, 21:48 UTC

Discorsi di Mercato

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mag 2026, 21:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

26 mag 2026, 20:58 UTC

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 19:22 UTC

Discorsi di Mercato

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mag 2026, 19:17 UTC

Discorsi di Mercato

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mag 2026, 18:56 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mag 2026, 18:03 UTC

Discorsi di Mercato

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mag 2026, 17:42 UTC

Discorsi di Mercato

Grains Await Fresh Trading Catalyst -- Market Talk

26 mag 2026, 17:33 UTC

Discorsi di Mercato

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mag 2026, 17:21 UTC

Discorsi di Mercato

Canada Faces a Labor Market Squeeze -- Market Talk

26 mag 2026, 16:52 UTC

Discorsi di Mercato

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mag 2026, 16:43 UTC

Discorsi di Mercato

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mag 2026, 16:24 UTC

Discorsi di Mercato

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mag 2026, 16:21 UTC

Discorsi di Mercato

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Auto & Transport Roundup: Market Talk

26 mag 2026, 16:16 UTC

Discorsi di Mercato

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mag 2026, 16:01 UTC

Discorsi di Mercato

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mag 2026, 15:21 UTC

Discorsi di Mercato

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

66.81% in crescita

Previsioni per 12 mesi

Media 20 USD 66.81%

Alto 20 USD

Basso 20 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

7 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.